Market Cap (In AUD)
9.47 Million
Revenue (In AUD)
1.73 Million
Net Income (In AUD)
-5.38 Million
Avg. Volume
421.28 Thousand
- Currency
- AUD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.015-0.041
- PE
- -
- EPS
- -
- Beta Value
- 0.607
- ISIN
- AU0000001AD2
- CUSIP
- Q0101X107
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D.
- Employee Count
- -
- Website
- https://adalta.com.au
- Ipo Date
- 2016-08-22
- Details
- AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd. to develop CAR-T cell products against various solid tumor antigens. AdAlta Limited was incorporated in 2006 and is headquartered in Bundoora, Australia.
More Stocks
-
INDRANIBIndrayani Biotech Limited
INDRANIB
-
001206
-
CRNZFCapricorn Energy PLC
CRNZF
-
YKEN
-
ETIL
-
012690Monalisa Co., Ltd
012690
-
ALMASMastrad Société Anonyme
ALMAS
-
PDPTFPUDO Inc.
PDPTF